Why a Publicly Traded Biopharmaceutical Company Chose Software Over Services — and Saved More Than $21 Million in Unjustified Vendor Charges

COMPANY

This company is a publicly traded biopharma organization with an active portfolio of 14 clinical trials. The R&D accounting function – responsible for accruals, investigator grants, vendor management, and SOX-compliant close processes across every active study – is led by a former Big 4 auditor who knows exactly what "audit-ready" actually means. With trials spanning multiple countries and vendor relationships, the finance team's ability to produce accurate, auditable numbers every period is not a back-office function. It is how the company defends its financials to auditors, investors, and the board.

CHALLENGE

Before Condor, clinical trial accounting ran entirely on Excel – a 20-tab workbook that required the team to manually build accruals for patient costs, pass-throughs, investigator fees, and other vendor obligations every close cycle. As the reviewer, the Senior Director of Finance for R&D spent the majority of her time not analyzing results, but verifying that equations were correct, that tabs were linking properly, and that no rows had been missed. Clerical errors occasionally surfaced after the fact regardless, and even with maximum diligence, the process was structurally unreliable.

"We were spending all of our time just making sure the equations were right, that the tabs were linking together, and you'd still find clerical errors after the fact. That frustration of spending my time on the wrong things ultimately brought us to looking for something better."
– Controller, Biopharma

The message was clear: the spreadsheet-based process was not producing sufficiently precise financial data, and the team was spending its time maintaining a mechanism rather than interrogating its output.

The team evaluated their options carefully. Auxilius’s model gave the team pause: it was service-heavy, offshore-supported, and structured so that Auxilius staff would perform uploads and implement changes on the client's behalf. For a team running on a tight close schedule, waiting 24 hours for a vendor to make an adjustment was operationally untenable. They needed a system their own team could control.

SOLUTION

Condor offered what neither Excel nor Auxilius could: a purpose-built software platform the team could operate themselves, with the accuracy and auditability that the existing spreadsheet process lacked, at an attractive price point. Investigator grant accounting, previously approximated at the country level, moved to exact cost by site by visit, which eliminated the core audit finding in one step.

The amendment-in-progress feature proved particularly valuable for the team's close workflow. When a change order enters the system, the  Senior Director of Finance for R&D reviews it with her team, clears comments (typically three to five on any given change order), and — when timing allows — implements it within the current close period. When it cannot be fully processed in period, Condor shows the financial impact of the pending amendment, allowing the team to accrue accordingly and implement cleanly the following quarter. This replaced a manual, judgment-dependent process with one that is documented, reviewable, and audit-ready by design.

The self-service model was not incidental – it was the deciding factor. The Controller's team handles all PO, invoice, and EDC uploads directly. Changes are made in real time, reviewed and cleared by the Controller, and journal entries are booked once everything is signed off. The Condor customer success team provides backup support when edge cases arise – which across 14 active studies happens roughly once per close cycle – but day-to-day, the team runs the process end-to-end. That operational ownership was not available with the service-provider alternative.

RESULTS

• $21M in vendor change orders recently challenged and rejected – a $20M increase request on one study pushed back in 2025, and a $1 million follow-up attempt on the same study rejected in 2026; both rebuffed with Condor data as the basis for negotiation.
• Scaled from 6 trials (3 staff) to 14 trials (4 staff) without backfilling a headcount loss – absorbing more than 2x the trial volume with no proportional increase in team size
• Close cycle completed by the 25th of each month for a company running on a 4-4-5 calendar, with all journal entries booked before period end.
• Dropped parallel Excel tracking after a single quarter – the team launched a parallel run with spreadsheets, concluded Condor was more accurate, and abandoned the reconciliation before the quarter was complete.
• SOX compliance strengthened materially – auditors who initially recalculated the entire Condor output (and confirmed it was accurate) now rely on the platform's SOC 1 report; the financial close sign-off page provides continuous audit evidence without manual assembly.

"With Auxilius, my team couldn't immediately handle the adjustments I needed — waiting 24 hours for someone offshore to make a change wasn't going to work. With Condor, it was something my team could do themselves, but with support as needed. That’s the best-case scenario."
— Controller, Biopharma

‍